Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
201
-
Total 13F shares, excl. options
-
50.2M
-
Shares change
-
+738K
-
Total reported value, excl. options
-
$2.14B
-
Value change
-
+$29.2M
-
Put/Call ratio
-
0.54
-
Number of buys
-
85
-
Number of sells
-
-105
-
Price
-
$42.54
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q4 2021
259 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q4 2021.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 201 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.2M shares
of 62.7M outstanding shares and own 80.1% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.13M shares), FMR LLC (5.49M shares), VANGUARD GROUP INC (4.58M shares), Bellevue Group AG (3.23M shares), BlackRock Inc. (2.78M shares), STATE STREET CORP (2.17M shares), JPMORGAN CHASE & CO (1.56M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.42M shares), CITADEL ADVISORS LLC (1.1M shares), and BOXER CAPITAL, LLC (1.09M shares).
This table shows the top 201 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.